Analysts expect Summit Therapeutics to report a Q2 2026 loss of $0.26 per share on revenue of approximately $0.11 million, with the stock currently trading at $14.18 against a bullish average price target of $28.91. Investors are laser-focused on clinical updates for ivonescimab (SMT112), particularly the development of the HARMONi-3 trial following a disappointing interim analysis for its squamous cohort in May. The company is facing heightened scrutiny regarding its cash runway after reporting a $189.4 million net loss in Q1 and disclosing substantial doubt about its ability to continue as a going concern without further financing. Market participants are also looking ahead to the November 14, 2026, PDUFA date for ivonescimab in EGFR-mutated lung cancer, which remains a primary valuation driver.